(Q51739914)

11 April 2018

title

Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. (English)

1 reference

11 April 2018

lip and oral cavity carcinoma

main subject

phase I clinical trial

0 references

1 reference

3

Toshihiko Torigoe

1 reference

11 April 2018

Yoshihiko Hirohashi

4

Yoshihiko Hirohashi

1 reference

11 April 2018

Noriyuki Satō

12

Noriyuki Sato

1 reference

11 April 2018

Hiroko Asanuma

7

Hiroko Asanuma

1 reference

11 April 2018

Akari Takahashi

8

Akari Takahashi

1 reference

11 April 2018

Yoshitaka Michifuri

9

Yoshitaka Michifuri

1 reference

11 April 2018

Akihiro Miyazaki

1

Akihiro Miyazaki

1 reference

11 April 2018

Junichi Kobayashi

2

Junichi Kobayashi

1 reference

11 April 2018

Kenji Nakamori

10

Kenji Nakamori

1 reference

11 April 2018

Hiroyoshi Hiratsuka

13

Hiroyoshi Hiratsuka

1 reference

11 April 2018

author name string

Takashi Yamamoto

5

1 reference

11 April 2018

Akira Yamaguchi

6

1 reference

11 April 2018

Itaru Nagai

11

1 reference

11 April 2018

publication date

10 December 2010

1 reference

11 April 2018

published in

Cancer Science

1 reference

11 April 2018

volume

102

1 reference

11 April 2018

issue

2

1 reference

11 April 2018

page(s)

324-329

1 reference

11 April 2018

Current surgical treatment of squamous cell carcinoma of the head and neck

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Survivin expression in oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

Survivin as prognostic factor in squamous cell carcinoma of the oral cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2010.01789.X

10.1111/J.1349-7006.2010.01789.X

21 January 2018

Identifiers

DOI

1 reference

11 April 2018

1 reference

11 April 2018